Moderna shares soar 60% on melanoma vaccine trial success Financial TimesPersonalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial CNBCModerna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STATModerna's stock doubles on promising cancer-vaccine results MarketWatch
